Online Shop
Abacavir
Aceclofenac
Acyclovir
Adefovir
Alfuzosin
Amiloride
Amlodipine
Amoxycillin
Anastrozole
Atropine
Azathioprine
Azithromycin
Baclofen
Bencyclane
Bicalutamide
Bisacodyl
Bisoprolol
Bosentas
Brimonidine
Butenafine
Calcitriol
Capecitabine
Cefixime
Cefoperazone
Cefotetan
Clindamycin
Clobetasone
Clonidine
Cyclosporine
Cyclosporine
Dacarbazine
Desonide
Dextroamphetamine
Didanosine
Duloxetine
Dutasteride
Efavirenz
Emtricitabine
Estradiol
Etoricoxib
Felodipine
Fenofibrate
Finasteride
Flucloxacillin
Fluvoxamine
Formoterol
Formoterol-Budesonide
Gliclazide
Goserelin
Hepatitis
Hyaluronate
Hydrocortisone
Hydroxyurea
Hypromellose
Indinavir
Insulin
Irinotecan
Isotretinoin
Itopride
Ketoconazole
Lamivudine
Levosalbutamol
Linezolid
Lisinopril
Lopinavir
Mercaptopurine
Mesalazine
Mometasone
Mycophenolate
Nateglinide
Nebivolol
Nelfinavir
Nevirapine
Nitrendipine
Olmesartan
Ondansetron
Ormeloxifene
Ornidazole
Orphenadrine
Oseltamivir
Oxcarbazepine
Oxybutynin
Oxytetracycline
Paracetamol
Paracetamol
Piroxicam
Progestin
Propranolol
Pyrantel
Quetiapine
Rabeprazole
Ranolazine
Risedronate
Rizatriptan
Rosiglitazone
Salbutamol
Saquinavir
Sildenafil
Sorbitol
Sucralfate
Tamsulosin
Telmisartan
Tenofovir
Tobramycin
Torsemide
Venlafaxine
Voriconazole
Warfarin
Zolmitriptan

Nevirapine.

Without a Prescription

Nevirapine is prescribed for the treatment of HIV infection, once patients have been stabilized on the maintenance regimen of nevirapine 200 mg bd, and have demonstrated adequate tolerability to nevirapine.

Dosage

Adults
Nevirapine - 30 - 1 tablet twice daily for patients weighing < 60 kg
Nevirapine - 40 - 1 tablet twice daily for patients weighing > 60 kg

Nevirapine should not be administered to patients who have just initiated therapy with nevirapine. This is because an initial lead-in dosing of 200 mg nevirapine once daily for 2 weeks is recommended. Following this lead-in dose, a dose escalation (maintenance dose) to 200 mg nevirapine bd may be carried out in the absence of any hypersensitivity reactions.

Monitoring of patients
Clinical chemistry tests, which include liver function tests, should be performed prior to initiating lead-in nevirapine therapy and at appropriate intervals during therapy.

Dosage Adjustment
Lamivudine
Because it is a fixed-dose combination, Nevirapine should not be prescribed for patients requiring dosage adjustment, such as those with low body weight (<50 kg).

Nevirapine
No data are available to recommend a dosage of nevirapine in patients with hepatic dysfunction, renal insufficiency or undergoing dialysis.
Patients who interrupt nevirapine dosing for more than 7 days should restart the recommended dosing, using one 200 mg Nevimune tablet daily for the first 14 days (lead-in) in combination with the other antiretrovirals, followed by 200 mg twice daily using Nevirapine in the absence of any signs of hypersensitivity.
Nevirapine administration should be interrupted in patients experiencing moderate or severe liver function tests abnormalities (excluding GGT), until the liver function test elevations have returned to baseline. Nevirapine may then be restarted at 200 mg per day. Increasing the daily dose to 200 mg twice daily (using Nevirapine) should be done with caution, after extended observation. Nevirapine should be permanently discontinued if moderate or severe liver function test abnormalities recur.
Nevirapine should be discontinued if patients experience severe rash or a rash accompanied by constitutional findings. Patients experiencing mild to moderate rash during the 14-day lead-in period of 200 mg/day should not have their nevirapine dose increased or start therapy with Nevirapine until the rash has resolved.

Contraindications


Nevirapine is contraindicated:
- in patients with clinically significant hypersensitivity to any of the components contained in the formulation.
- for patients who are just initiating therapy with nevirapine. These patients require a lead-in dose of nevirapine 200 mg o.d., which has been shown to reduce the incidence of rash and development of hypersensitivity. Once patients have demonstrated adequate tolerability to Nevirapine during this time period, they can then be switched to Nevirapine, which contains the maintenance dose of nevirapine 200 mg b.d.
Thus, it is recommended that patients initiate therapy using a combination of Lamivir-S and Nevimune during the first two weeks, and then switch to Nevirapine once adequate tolerability is demonstrated.

Prescription drugs without a script
Prescription drugs no script
Prescription drugs no prescription
Prescription drugs without a prescription
RX no RX
RX without RX
2004 - 2017